Online citations, reference lists, and bibliographies.
← Back to Search

Antisense Delivery Using Protamine-oligonucleotide Particles.

M. Junghans, J. Kreuter, A. Zimmer
Published 2000 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Protamine, a polycationic peptide (mol. wt 4000-4500), was evaluated as a potential penetration enhancer for phosphodiester antisense oligonucleotides (ODNs). Unique complexes in the form of nanoparticles were spontaneously formed, which we call 'proticles'. The stability of the particles and the ODNs bound into the proticles was examined in foetal calf serum and cell culture medium. FITC-labelled ODNs bound to protamine showed an increased cellular uptake into human histiocytic lymphoma U 937 cells compared to free ODNs. Proticles significantly decreased cellular growth in a cell proliferation assay using ODNs against the c- myc proto-oncogene.
This paper references



This paper is referenced by
10.1515/BC.2001.060
Fluorescence Correlation Spectroscopy for the Characterisation of Drug Delivery Systems
F. Delie (2001)
10.1021/mp100272k
A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery.
Xiaojuan Yang (2011)
10.1016/j.talanta.2013.08.010
Gold nanoparticle coupled with fluorophore for ultrasensitive detection of protamine and heparin.
Jiangna Zhao (2013)
Cell-penetrating peptides; chemical modification, mechanism of uptake and formulation development
Kariem Ezzat (2012)
10.1016/j.ejps.2015.04.009
Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting.
B. Scheicher (2015)
10.1016/j.vaccine.2010.03.045
Generation and characterization of a fusion protein of single-chain fragment variable antibody against hemagglutinin antigen of avian influenza virus and truncated protamine.
Tao Zhang (2010)
The Austrian NANO Initiative: Small Country with Strong Expertise
E. Glenck (2005)
10.1159/000436990
Beyond Cholesterol - New Cardiovascular Biomarkers.
H. Mangge (2016)
10.1002/cbic.200390012
Solution Structure and Stability of Tryptophan‐Containing Nucleopeptide Duplexes
I. Gómez-Pinto (2003)
10.1016/J.JCONREL.2005.04.019
Oligonucleotide-protamine-albumin nanoparticles: Protamine sulfate causes drastic size reduction.
G. Mayer (2005)
10.4161/cbt.6.3.3662
The inhibitory effects of nanosize delivery system for antisense oligonucleotide of hTERT on EC9706 cells
Z. Zhang (2007)
10.1016/J.IJPHARM.2004.05.032
New protamine quantification method in microtiter plates using o-phthaldialdehyde/N-acetyl-L-cysteine reagent.
D. Lochmann (2004)
10.1016/J.EJPB.2004.04.001
Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization.
D. Lochmann (2005)
10.1016/j.jconrel.2012.04.026
In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice.
Y. S. Park (2012)
10.1515/ejnm-2014-0011
Anti-inflammatory mediators for molecular imaging of atherosclerosis
Gunter Almer (2014)
10.3390/pharmaceutics12050421
Encapsulating TGF-β1 Inhibitory Peptides P17 and P144 as a Promising Strategy to Facilitate Their Dissolution and to Improve Their Functionalization
N. A. Hanafy (2020)
10.1371/journal.pone.0164149
Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration
B. Scheicher (2016)
10.1016/j.ejps.2017.04.005
Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors
Lydia Ramzy (2017)
10.1016/j.jconrel.2008.05.011
Controlled delivery of anti-sense oligodeoxynucleotide from multilayered biocompatible phosphorylcholine polymer films.
Z. Zhang (2008)
10.1016/j.jconrel.2010.01.026
Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide.
Y. S. Park (2010)
10.3109/21691401.2014.913054
Effect of size on biological properties of nanoparticles employed in gene delivery
S. Prabha (2016)
10.1016/S0167-4838(00)00219-3
Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles.
M. Junghans (2001)
10.1533/9781908818645.237
12 – Protamine nanoparticles
Surendra Nimesh (2013)
10.1016/j.ejpb.2013.03.003
Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice.
I. Pali-Schöll (2013)
10.2147/IJN.S15239
New tumor-targeted nanosized delivery carrier for oligonucleotides: characteristics in vitro and in vivo
Tianyang Zhou (2011)
10.2174/0929867322666150716114625
Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging
G. Almer (2015)
10.1016/J.JCONREL.2004.08.027
Comparison of antisense oligonucleotide drug delivery systems.
J. Weyermann (2004)
eneration and characterization of a fusion protein of single-chain fragment ariable antibody against hemagglutinin antigen of avian influenza virus and runcated protamine
ao Zhanga (2010)
10.1002/jssc.201501093
Analysis of protamine peptides in insulin pharmaceutical formulations by capillary electrophoresis.
C. Lamalle (2016)
10.1021/bp060348j
Nanoparticle‐Mediated Drug Delivery and Gene Therapy
S. Jin (2007)
THEMED SECTION: VECTOR DESIGN AND DRUG DELIVERY REVIEW Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA
E. Fattal (2009)
10.1016/j.ijbiomac.2015.08.006
Recent advancement of gelatin nanoparticles in drug and vaccine delivery.
N. Sahoo (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar